*This is the Global version of our site. For specific country information, please choose from the dropdown.
Global Disclosure Statement
Novavax is committed to transparency in our engagements with healthcare professionals, healthcare organizations, and patient advocacy organizations.
We honor all global transparency requirements. In doing so, we diligently record all transfers of value to healthcare professionals and organizations, and we report these transactions pursuant to all the applicable laws, regulations, and codes of conduct governing the transparency of these interactions to ensure public trust and confidence.
We publicly disclose the transfers of value through applicable government portals and the Novavax website.
In the United States, our data are publicly accessible via the Centers for Medicare & Medicaid Services' Open Payments Program in accordance with the Physician Payments Sunshine Act. You can access their website here.
In the European Union, we are a member of EFPIA’s Vaccines Europe and endorse the EFPIA Disclosure Code, a set of guiding principles that requires pharmaceutical companies to publicly disclose transfers of value made to European healthcare professionals and healthcare organizations.
Please see the Methodological Notes to read a summary of the methodologies used to identify, collect, and prepare transfers of value for disclosure. Select from the countries below for more information.
If you have questions on the data contained in the reports, please contact Novavax's Global Spend Transparency staff at [email protected].